Postural tachycardia syndrome (POTS) and other autonomic disorders in antiphospholipid (Hughes) syndrome (APS)

Lupus

Volumn 23, Issue 7, 2014, Pages 697-702

  Schofield, J R ^a   Blitshteyn, S ^b   Shoenfeld, Y ^c,d   Hughes, G R V ^e  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

^e LONDON BRIDGE HOSPITAL   (United Kingdom)

Author keywords

Antiphospholipid syndrome (APS); Autonomic disorders; Hughes syndrome; Intravenous immunoglobulin (IVIG); Neurocardiogenic syncope (NCS); Postural tachycardia syndrome (POTS)

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADOLESCENT; ADULT; AGED; AMNESIA; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTONOMIC DYSFUNCTION; BALANCE DISORDER; CEREBRAL SINUS THROMBOSIS; CLINICAL ARTICLE; FAINTNESS; FEMALE; GUILLAIN BARRE SYNDROME; HEMIPLEGIC MIGRAINE; HUMAN; JOINT LAXITY; KIDNEY ARTERY STENOSIS; LIVEDO RETICULARIS; LUNG EMBOLISM; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MIGRAINE; MYELITIS; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SPONTANEOUS ABORTION; STRESS FRACTURE; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TRIGEMINUS NEURALGIA; VENOUS THROMBOEMBOLISM; AUTONOMIC NERVOUS SYSTEM DISEASES; COMPLICATION; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; AUTONOMIC NERVOUS SYSTEM DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84903602791     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314524468     Document Type: Article

References (42)

1. Koniari I, Siminelakis SN, Baikoussis NG, Papadopoulos G, Goudevenos J, Apostolakis E. Antiphospholipid syndrome; its implication in cardiovascular diseases: A review. J Cardiothorac Surg 2010; 5: 101-111.
2. Tenedios F, Erkan K, Lockshin MD. Cardiac involvement in the antiphospholipid syndrome. Lupus 2005; 14: 691-696.
3. Silbiger JJ. The cardiac manifestations of antiphospholipid syndrome and their echocardiographic recognition. J Am Soc Echocardiogr 2009; 22: 1100-1108.
4. Scantlebury DC, Nkomo VT, Enriquez-Sarano M. Antiphospholipid syndrome and recurrent thrombotic valve disease. J Am Coll Cardiol 2013; 61: e177.
5. Nair S, Khamashta MA, Hughes GRV. Syndrome X and Hughes syndrome. Lupus 2002; 11: 332.
6. Christodoulou C, Sangle S, D'Cruz DP. Vasculopathy and arterial stenotic lesions in the antiphospholipid syndrome. Rheumatology (Oxford) 2007; 46: 907-910.
7. Tektonidou MG. Renal Involvement in the antiphospholipid syndrome (APS)-APS nephropathy. Clin Rev Allergy Immunol 2009; 36: 131-140.
8. Sangle S, D'Cruz DP, Khamashta MA, Hughes GRV. Antiphospholipid antibodies, systemic lupus erythematosus, and non-traumatic metatarsal fractures. Ann Rheum Dis 2004; 63: 1241-1243.
9. Uthman I, Godeau B, Taher A, Khamastha M. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev 2008; 22: 187-194.
10. France's C, Niang S, Laffitte E, Pelletier FI, Costedoat N, Piette JC. Dermatologic manifestations of the antiphospholipid syndrome: Two hundred consecutive cases. Arthritis Rheum 2005; 52: 1785-1793.
11. Sanna G, D'Cruz D, Cuadrado MJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin North Am 2006; 32: 465-490.
12. Hughes GRV. Connective tissue disease and the skin. Clin Exp Dermatol 1984; 9: 534-544.
13. Bilora F, Biasiolo M, Zancan A, et al. Autonomic dysfunction and primary antiphospholipid syndrome: A frequent and frightening correlation? Int J Gen Medx2012; 5:339-343
14. Garcia C, Perandini L, Seguro L, et al. Impaired aerobic exercise capacity and cardiac autonomic control in primary antiphospholipid syndrome. Lupus 2013; 22: 928-931.
15. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
16. Raj SR. Postural tachycardia syndrome (POTS). Circulation 2013; 127: 2336-2342.
17. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement of the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci 2011; 161: 46-48.
18. Tsutsumi A, Horita T, Ohmuro J, et al. Reflex sympathetic dystrophy in a patient with the antiphospholipid syndrome. Lupus 1999; 8: 471-473.
19. Shoenfeld Y. Systemic antiphospholipid syndrome. Lupus 2003; 12: 497-498.
20. Hughes GRV. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. BMJ 1983; 287: 1088-1089.
21. Hughes GRV. Heparin, antiphospholipid antibodies and the brain. Lupus 2012; 21: 1039-1040.
22. Harper BE, Wills R, Pierangeli SS. Pathophysiological mechanisms in antiphospholipid syndrome. Int J Clin Rheumtol 2011; 6: 157-171.
23. Shoenfeld Y, Nahum A, Korczyn AD, et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003; 12: 436-442.
24. Benrud-Larson LM, Dewar MS, Sandroni P, Rummans TA, Haythornthwaite JA, Low PA. Quality of life in patients with postural tachycardia syndrome. Mayo Clin Proc 2002; 77: 531-537.
25. Thieben MJ, Sandroni P, Sletten DM, et al. Postural orthostatic tachycardia syndrome: The Mayo clinic experience. Mayo Clin Proc 2007; 82: 308-313.
26. Kanjwal K, Karabin B, Kanjwal Y, Grubb BP. Autonomic dysfunction presenting as postural tachycardia syndrome following traumatic brain injury. Cardiol J 2010; 17: 482-487.
27. Blitshteyn S. Postural tachycardia syndrome following human papillomavirus vaccination. Eur J Neurol 2014; 21: 135-139.
28. Shibao C, Arzubiaga C, Roberts LJ, et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension 2005; 45: 385-390.
29. Kanjwal K, Karabin B, Kanjwal Y, Grubb BP. Postural orthostatic tachycardia syndrome following Lyme disease. Cardiol J 2011; 18: 63-66.
30. Kanjwal K, Saeed B, Karabin B, Kanjwal Y, Grubb B. Comparative clinical profile of postural orthostatic tachycardia patients with and without joint hypermobility syndrome. Indian Pacing Electrophysiol J 2010; 10: 173-178.
31. Stojanovich L. Autonomic dysfunction in autoimmune rheumatic disease. Autoimmun Rev 2009; 8: 569-572.
32. Honczarenko K, Budzianowska A, Ostanek L. Neurological syndromes in systemic lupus erythematosus and their association with antiphospholipid syndrome. Neurol Neurochir Pol 2008; 42: 513-517.
33. Afeltra A, Garzia P, Mitterhofer AP, et al. Neuropsychiatric lupus syndromes: Relationship with antiphospholipid antibodies. Neurology 2003; 61: 108-110.
34. Wang XL, Chai Q, Charlesworth MC, et al. Autoimmunoreactive IgGs from patients with postural tachycardia syndrome. Proteomics Clin Appl 2012; 6: 615-625.
35. Li H, Kem DC, Reim S, et al. Agonistic autoantibodies as vasodilators in orthostatic hypotension: A new mechanism. Hypertension 2012; 59: 402-408.
36. Iodice V, Kimpinski K, Vernino S, Sandroni P, Fealey RD, Low PA. Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy. Neurology 2009; 72: 2002-2008.
37. Cuadrado MJ, Khamashta MA, D'Cruz D, Hughes GR. Migraine in Hughes syndrome-heparin as a therapeutic trial? QJM 2001; 94: 114-115.
38. Oaklander AL, Klein MM. Evidence of small-fiber polyneuropathy in unexplained, juvenile-onset, widespread pain syndromes. Pediatrics 2012; 131: 2597-2607.
39. Novak P, Williams A, Ravin P, Zurkiya O, Abduljalil A, Novak V. Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurol 2012; 12: 131.
40. Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology 1999; 39: 421-426.
41. Sciascia S, Lopez-Pedrera C, Roccatello D, Cuadrado MJ. Catastrophic antiphospholipid syndrome (CAPS). Best Pract Res Clin Rheumatol 2012; 26: 535-541.
42. Erkan D, Vega J, Ramón G, Kozora E, Lockshin MD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum 2013; 65: 464-471.